Skip to main content
NCBI home page
The BMJ logoLink to The BMJ
. 1996 Jun 8;312(7044):1465–1469. doi: 10.1136/bmj.312.7044.1465

Clinical immunology.

T E Mollnes 1, M Harboe 1
PMCID: PMC2351204  PMID: 8664630

Full text

PDF
1465

Images in this article

1467Fig 1
on p.1467

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Begue R. E., Castellares G., Ruiz R., Hayashi K. E., Sanchez J. L., Gotuzzo E., Oberst R. B., Taylor D. N., Svennerholm A. M. Community-based assessment of safety and immunogenicity of the whole cell plus recombinant B subunit (WC/rBS) oral cholera vaccine in Peru. Vaccine. 1995 May;13(7):691–694. doi: 10.1016/0264-410x(94)00056-s. [DOI] [PubMed] [Google Scholar]
  2. Couser W. G., Johnson R. J., Young B. A., Yeh C. G., Toth C. A., Rudolph A. R. The effects of soluble recombinant complement receptor 1 on complement-mediated experimental glomerulonephritis. J Am Soc Nephrol. 1995 May;5(11):1888–1894. doi: 10.1681/ASN.V5111888. [DOI] [PubMed] [Google Scholar]
  3. Cryz S. J., Jr, Kaper J., Tacket C., Nataro J., Levine M. M. Vibrio cholerae CVD103-HgR live oral attenuated vaccine: construction, safety, immunogenicity, excretion and non-target effects. Dev Biol Stand. 1995;84:237–244. [PubMed] [Google Scholar]
  4. Edwards K. M., Decker M. D. Acellular pertussis vaccines for infants. N Engl J Med. 1996 Feb 8;334(6):391–392. doi: 10.1056/NEJM199602083340609. [DOI] [PubMed] [Google Scholar]
  5. Foreman K. E., Vaporciyan A. A., Bonish B. K., Jones M. L., Johnson K. J., Glovsky M. M., Eddy S. M., Ward P. A. C5a-induced expression of P-selectin in endothelial cells. J Clin Invest. 1994 Sep;94(3):1147–1155. doi: 10.1172/JCI117430. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Gautreau C., Kojima T., Woimant G., Cardoso J., Devillier P., Houssin D. Use of intravenous immunoglobulin to delay xenogeneic hyperacute rejection. An in vivo and in vitro evaluation. Transplantation. 1995 Nov 15;60(9):903–907. [PubMed] [Google Scholar]
  7. Greco D., Salmaso S., Mastrantonio P., Giuliano M., Tozzi A. E., Anemona A., Ciofi degli Atti M. L., Giammanco A., Panei P., Blackwelder W. C. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. N Engl J Med. 1996 Feb 8;334(6):341–348. doi: 10.1056/NEJM199602083340601. [DOI] [PubMed] [Google Scholar]
  8. Gustafsson L., Hallander H. O., Olin P., Reizenstein E., Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med. 1996 Feb 8;334(6):349–355. doi: 10.1056/NEJM199602083340602. [DOI] [PubMed] [Google Scholar]
  9. Haviland D. L., McCoy R. L., Whitehead W. T., Akama H., Molmenti E. P., Brown A., Haviland J. C., Parks W. C., Perlmutter D. H., Wetsel R. A. Cellular expression of the C5a anaphylatoxin receptor (C5aR): demonstration of C5aR on nonmyeloid cells of the liver and lung. J Immunol. 1995 Feb 15;154(4):1861–1869. [PubMed] [Google Scholar]
  10. Høgåsen K., Jansen J. H., Mollnes T. E., Hovdenes J., Harboe M. Hereditary porcine membranoproliferative glomerulonephritis type II is caused by factor H deficiency. J Clin Invest. 1995 Mar;95(3):1054–1061. doi: 10.1172/JCI117751. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Jenkins P. G., Coombes A. G., Yeh M. K., Thomas N. W., Davis S. S. Aspects of the design and delivery of microparticles for vaccine applications. J Drug Target. 1995;3(1):79–81. doi: 10.3109/10611869509015939. [DOI] [PubMed] [Google Scholar]
  12. Kilgore K. S., Shen J. P., Miller B. F., Ward P. A., Warren J. S. Enhancement by the complement membrane attack complex of tumor necrosis factor-alpha-induced endothelial cell expression of E-selectin and ICAM-1. J Immunol. 1995 Aug 1;155(3):1434–1441. [PubMed] [Google Scholar]
  13. Kniskern P. J., Marburg S., Ellis R. W. Haemophilus influenzae type b conjugate vaccines. Pharm Biotechnol. 1995;6:673–694. doi: 10.1007/978-1-4615-1823-5_30. [DOI] [PubMed] [Google Scholar]
  14. Kooyman D. L., Byrne G. W., McClellan S., Nielsen D., Tone M., Waldmann H., Coffman T. M., McCurry K. R., Platt J. L., Logan J. S. In vivo transfer of GPI-linked complement restriction factors from erythrocytes to the endothelium. Science. 1995 Jul 7;269(5220):89–92. doi: 10.1126/science.7541557. [DOI] [PubMed] [Google Scholar]
  15. Krause I., Blank M., Kopolovic J., Afek A., Goldberg I., Tomer Y., Shoenfeld Y. Abrogation of experimental systemic lupus erythematosus and primary antiphospholipid syndrome with intravenous gamma globulin. J Rheumatol. 1995 Jun;22(6):1068–1074. [PubMed] [Google Scholar]
  16. LaVecchio J. A., Dunne A. D., Edge A. S. Enzymatic removal of alpha-galactosyl epitopes from porcine endothelial cells diminishes the cytotoxic effect of natural antibodies. Transplantation. 1995 Oct 27;60(8):841–847. [PubMed] [Google Scholar]
  17. Magee J. C., Collins B. H., Harland R. C., Lindman B. J., Bollinger R. R., Frank M. M., Platt J. L. Immunoglobulin prevents complement-mediated hyperacute rejection in swine-to-primate xenotransplantation. J Clin Invest. 1995 Nov;96(5):2404–2412. doi: 10.1172/JCI118297. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. McCoy R., Haviland D. L., Molmenti E. P., Ziambaras T., Wetsel R. A., Perlmutter D. H. N-formylpeptide and complement C5a receptors are expressed in liver cells and mediate hepatic acute phase gene regulation. J Exp Med. 1995 Jul 1;182(1):207–217. doi: 10.1084/jem.182.1.207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. McCurry K. R., Kooyman D. L., Alvarado C. G., Cotterell A. H., Martin M. J., Logan J. S., Platt J. L. Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury. Nat Med. 1995 May;1(5):423–427. doi: 10.1038/nm0595-423. [DOI] [PubMed] [Google Scholar]
  20. Medaglini D., Pozzi G., King T. P., Fischetti V. A. Mucosal and systemic immune responses to a recombinant protein expressed on the surface of the oral commensal bacterium Streptococcus gordonii after oral colonization. Proc Natl Acad Sci U S A. 1995 Jul 18;92(15):6868–6872. doi: 10.1073/pnas.92.15.6868. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Miletic V. D., Hester C. G., Frank M. M. Regulation of complement activity by immunoglobulin. I. Effect of immunoglobulin isotype on C4 uptake on antibody-sensitized sheep erythrocytes and solid phase immune complexes. J Immunol. 1996 Jan 15;156(2):749–757. [PubMed] [Google Scholar]
  22. Mollnes T. E., Høgåsen K., Hoaas B. F., Michaelsen T. E., Garred P., Harboe M. Inhibition of complement-mediated red cell lysis by immunoglobulins is dependent on the IG isotype and its C1 binding properties. Scand J Immunol. 1995 May;41(5):449–456. doi: 10.1111/j.1365-3083.1995.tb03591.x. [DOI] [PubMed] [Google Scholar]
  23. Qi M., Schifferli J. A. Inhibition of complement activation by intravenous immunoglobulins. Arthritis Rheum. 1995 Jan;38(1):146–146. doi: 10.1002/art.1780380123. [DOI] [PubMed] [Google Scholar]
  24. Quigg R. J., Holers V. M., Morgan B. P., Sneed A. E., 3rd Crry and CD59 regulate complement in rat glomerular epithelial cells and are inhibited by the nephritogenic antibody of passive Heymann nephritis. J Immunol. 1995 Apr 1;154(7):3437–3443. [PubMed] [Google Scholar]
  25. Quinti I., Pandolfi F., Paganelli R., el Salman D., Giovannetti A., Rosso R., Oliva A., Rainaldi L., Aiuti F. HCV infection in patients with primary defects of immunoglobulin production. Clin Exp Immunol. 1995 Oct;102(1):11–16. doi: 10.1111/j.1365-2249.1995.tb06629.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Rinder C. S., Rinder H. M., Smith B. R., Fitch J. C., Smith M. J., Tracey J. B., Matis L. A., Squinto S. P., Rollins S. A. Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation. J Clin Invest. 1995 Sep;96(3):1564–1572. doi: 10.1172/JCI118195. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Rosengard A. M., Cary N. R., Langford G. A., Tucker A. W., Wallwork J., White D. J. Tissue expression of human complement inhibitor, decay-accelerating factor, in transgenic pigs. A potential approach for preventing xenograft rejection. Transplantation. 1995 May 15;59(9):1325–1333. [PubMed] [Google Scholar]
  28. Ross C., Svenson M., Hansen M. B., Vejlsgaard G. L., Bendtzen K. High avidity IFN-neutralizing antibodies in pharmaceutically prepared human IgG. J Clin Invest. 1995 May;95(5):1974–1978. doi: 10.1172/JCI117881. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Ruiz de Souza V., Carreno M. P., Kaveri S. V., Ledur A., Sadeghi H., Cavaillon J. M., Kazatchkine M. D., Haeffner-Cavaillon N. Selective induction of interleukin-1 receptor antagonist and interleukin-8 in human monocytes by normal polyspecific IgG (intravenous immunoglobulin). Eur J Immunol. 1995 May;25(5):1267–1273. doi: 10.1002/eji.1830250521. [DOI] [PubMed] [Google Scholar]
  30. Saadi S., Holzknecht R. A., Patte C. P., Stern D. M., Platt J. L. Complement-mediated regulation of tissue factor activity in endothelium. J Exp Med. 1995 Dec 1;182(6):1807–1814. doi: 10.1084/jem.182.6.1807. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Saadi S., Platt J. L. Transient perturbation of endothelial integrity induced by natural antibodies and complement. J Exp Med. 1995 Jan 1;181(1):21–31. doi: 10.1084/jem.181.1.21. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Saiki O., Tanaka T., Wada Y., Uda H., Inoue A., Katada Y., Izeki M., Iwata M., Nunoi H., Matsuda I. Signaling through CD40 rescues IgE but not IgG or IgA secretion in X-linked immunodeficiency with hyper-IgM. J Clin Invest. 1995 Feb;95(2):510–514. doi: 10.1172/JCI117692. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Sandrin M. S., Fodor W. L., Mouhtouris E., Osman N., Cohney S., Rollins S. A., Guilmette E. R., Setter E., Squinto S. P., McKenzie I. F. Enzymatic remodelling of the carbohydrate surface of a xenogenic cell substantially reduces human antibody binding and complement-mediated cytolysis. Nat Med. 1995 Dec;1(12):1261–1267. doi: 10.1038/nm1295-1261. [DOI] [PubMed] [Google Scholar]
  34. Smiley J. D., Talbert M. G. Southwestern Internal Medicine Conference: high-dose intravenous gamma globulin therapy: how does it work? Am J Med Sci. 1995 May;309(5):295–303. doi: 10.1097/00000441-199530950-00010. [DOI] [PubMed] [Google Scholar]
  35. Toungouz M., Denys C. H., De Groote D., Dupont E. In vitro inhibition of tumour necrosis factor-alpha and interleukin-6 production by intravenous immunoglobulins. Br J Haematol. 1995 Apr;89(4):698–703. doi: 10.1111/j.1365-2141.1995.tb08404.x. [DOI] [PubMed] [Google Scholar]
  36. Vassilev T. L., Bineva I. L., Dietrich G., Kaveri S. V., Kazatchkine M. D. Variable region-connected, dimeric fraction of intravenous immunoglobulin enriched in natural autoantibodies. J Autoimmun. 1995 Jun;8(3):405–413. doi: 10.1006/jaut.1995.0032. [DOI] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES